Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sulfasalazine in Active Systemic Lupus Erythematosus
NCT06360068Phase 2Not yet recruiting
- Start
- May 2024
- Primary completion
- May 2025
- Modality
- Small Molecules
01
Overview
A Phase 2 trial of 5-aminosalicylic acid + sulphasalazine in systemic lupus erythematosus (SLE). Planned start May 2024; status: not yet recruiting.
02
Drugs
5-aminosalicylic acid + sulphasalazine
03
Conditions
systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on NCT06360068.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06360068.